Posted by Michael Wonder on 23 Jan 2017
Conditional marketing authorisations give patients access to important new medicines earlier
23 January 2017 - EMA publishes report with data collected between 2006 and June 2016.
Conditional marketing authorisation can speed up access to medicines for patients with unmet medical needs. Since 2006, a total of 30 medicines have received a conditional marketing authorisation.
Medicines that were granted a conditional marketing authorisation target seriously debilitating or life-threatening conditions such as HIV infection, breast cancer, severe epilepsy in infants or multi-drug resistant tuberculosis. 14 were orphan medicines, providing patients suffering from rare diseases with new therapeutic options. These are some of the findings of a report by the EMA to mark ten years of experience with CMA.
